The correlation between Streptococcus pneumoniae serotypes, biofilm production, antibiotic susceptibility and drug efflux in isolates from patients suffering from acute exacerbations of chronic bronchitis (AECB) remains largely unexplored. Using 101 isolates collected from AECB patients for whom partial (n = 51) or full (n = 50) medical details were available, we determined serotypes (ST)/serogroups (SG) (Quellung reaction), antibiotic susceptibility patterns [MIC (microdilution) using EUCAST and CLSI criteria] and ability to produce biofilm in vitro (10-day model; crystal violet staining). The majority of patients were 55-75 years old and <5% were vaccinated against S. pneumoniae. Moreover, 54% showed high severity scores (GOLD 3-4), and comorbidities were frequent including hypertension (60%), cancer (24%) and diabetes (20%). Alcohol and/or tobacco dependence was >30%. Isolates of SG6-11-15-23, known for large biofilm production and causing chronic infections, were the most prevalent (>15% each), but other isolates also produced biofilm (SG9-18-22-27 and ST8-20 being most productive), except SG7, SG29 and ST5 (<2% of isolates each). Resistance (EUCAST breakpoints) was 8-13% for amoxicillin and cefuroxime, 35-39% for macrolides, 2-8% for fluoroquinolones and 2% for telithromycin. ST19A isolates showed resistance to all antibiotics, ST14 to all except moxifloxacin, and SG9 and SG19 to all except telithromycin, moxifloxacin and ceftriaxone (SG19 only). Solithromycin and telithromycin MICs were similar. No correlation was observed between biofilm production and MIC or efflux (macrolides, fluoroquinolones). S. pneumoniae serotyping may improve AECB treatment by avoiding antibiotics with predictable low activity, but it is not predictive of biofilm production.
Introduction
Chronic obstructive pulmonary disease (COPD) remains one of the major causes of morbidity and mortality worldwide, occupying the fourth place for death since 2000 and predicted to reach third place in 2020 [1, 2] . At increasingly closer intervals, COPD patients suffer from acute exacerbations of chronic bronchitis (AECB), which contribute to alteration of their respiratory function. These episodes are characterised by increased dyspnoea, coughing and sputum production, being evidence of infection of the airways [3] . Bacterial pathogens are found in 50-80% of cases of AECB [4] , with Streptococcus pneumoniae being one of the dominant species [1, 4] . Recurrence of infections associated with bacterial persistence results in frequent antibiotic courses. This favours the emergence of multiresistance of S. pneumoniae [5] through a variety of non-mutually exclusive mechanisms such as alterations in the antibiotic targets for ␤-lactams and macrolides as well as overexpression of efflux pumps for macrolides and fluoroquinolones [6] . Biofilm formation also favours the persistence of S. pneumoniae in the airways [7] . Up to 80% of chronic infections involve pneumococcal growth and survival within biofilms [8, 9] , in direct relation to the ability of this organism to colonise the nasopharynx [10] , which may be dependent on its serotype (ST)/serogroup (SG) [11] . Whilst more than 90 distinct STs have been described for S. pneumoniae [12] , few studies have attempted to examine what correlations exist between ST and/or SG and the ability to form thick biofilms in clinical isolates from patients with COPD [1] . Moreover, none of these studies have extended the correlations to key properties of the isolates such as their susceptibility to commonly recommended antibiotics and the expression of efflux transporters. Since efflux is critical in other bacteria for liberating quorum-sensing signalling molecules involved in biofilm formation [13] , we also investigated the relationship between the ability of S. pneumoniae to form biofilm and the presence of phenotypic efflux for macrolides and ciprofloxacin.
In the present report, we show (i) that the susceptibility of S. pneumoniae isolates from COPD patients to ␤-lactams and fluoroquinolones is lower than that seen for patients with a confirmed diagnosis of bacterial community-acquired pneumonia (CAP) [14] , (ii) that most of these isolates produce large amounts of biofilm irrespective of their ST/SG and (iii) that there is no correlation between the ability for biofilm formation in vitro and susceptibility to antibiotics or efflux towards macrolides or fluoroquinolones amongst the isolates investigated.
Materials and methods

General outline of the clinical study, patient selection and medical data acquisition
A first series of isolates consisted of 48 non-duplicate S. pneumoniae strains obtained between March 2006 and December 2008 from patients with a declared diagnosis of AECB and was assembled at the Belgian Scientific Institute of Public Health (Brussels, Belgium). Samples from this collection were equally distributed between the Belgian provinces in relation to their population. The second series of isolates consisted of 53 non-duplicate strains obtained in a prospective fashion between November 2010 and May 2013. For this purpose, five hospitals (one teaching and four non-teaching) were contacted and asked to enrol patients with a suspicion of AECB whether self-referred or referred by a general practitioner. Patients were enrolled upon obtaining a sample of sputum from the lower respiratory tract fulfilling the microbiological interpretive criteria of an acceptable specimen for culture [abundance of white blood cells (WBCs), few epithelial cells at low-power magnification, and ≥10-25 WBCs with no epithelial cells under 1000× magnification]. Only patients with samples yielding a positive culture for S. pneumoniae and with a confirmed diagnosis of AECB based on Anthonisen's criteria [3] were retained. For 50 of these patients, the whole medical data could be collected and was anonymised. Patients were stratified based on the severity scores (1-4 classification of the 2013 edition of the Global Initiative for Chronic Obstructive Lung Disease [GOLD] report [15] ), sex, age, length of hospitalisation, geographical location, co-morbidities, smoking habit and therapeutic treatment at admission. Smoking habits were obtained from the patient's declaration. Tobacco usage was converted into 'pack × year' units by multiplying the number of packs smoked per day by the number of years as a smoker (using a threshold of >20 for increased risk of tobacco-related cancer [16] ).
Bacterial strains and growth conditions
After identification in each clinical laboratory, strains were stored at −80 • C for transfer to a central laboratory until used for our experiments. Confirmation of identification was made by growth inhibition by optochin (Oxoid Ltd., Basingstoke, UK), and serotyping was performed as previously described [17] . Streptococcus pneumoniae ATCC 49619 strain (capsulated ST19F [18] ) was used for quality control in each set of experiments. All strains were grown on Mueller-Hinton blood agar plates supplemented with 5% defibrinated horse blood incubated at 37 • C in a 5% CO 2 atmosphere.
Susceptibility testing
Minimum inhibitory concentrations (MICs) were determined by microdilution following the guidelines of the Clinical and Laboratory Standards Institute (CLSI) [19] . MICs were read after 18-24 h of incubation at 37 • C. To improve accuracy, concentrations at half a value of each standard geometric progression were used as previously described [14] over the whole concentration range investigated. MICs were categorised as susceptible, intermediate or resistant according to the CLSI and European Committee on Antimicrobial Susceptibility Testing (EUCAST) interpretive breakpoints [19, 20] .
Assessment of efflux phenotypes
The efflux resistance phenotype to macrolides was determined by examining the dissociation of susceptibilities between clarithromycin and clindamycin (substrate and non-substrate of the macrolide efflux transporters, respectively [14] ). Efflux of fluoroquinolones was detected by a decrease in the MIC upon addition of reserpine (10 mg/L), an inhibitor of both PatA/B and PmrA fluoroquinolone efflux transporters in S. pneumoniae [14] .
In vitro development of biofilms and determination of biofilm mass
Ninety-six well plates (European cat. no. 734-2327; VWR, Radnor, PA) were used as the support for biofilm growth. In each well, 25 L of bacterial culture [optical density at 620 nm (OD 620 ) = 0.1] were added to 175 L of cation-adjusted Mueller-Hinton broth supplemented with 5% lysed horse blood (Oxoid Ltd.) and 2% glucose as previously described [18] . Biofilm development was obtained by incubation for 2-10 days at 37 • C in a 5% CO 2 atmosphere with medium replacement every 48 h. Biofilms examined after 2 days or 10 days are referred to as young and mature biofilms, respectively. Biofilm mass was evaluated by staining with crystal violet followed by measuring the absorbance exactly as previously described [18] . Each isolate was tested twice at different dates, with each assay using three to six measures. The mean coefficient of variation of the assay was 12.3% (extremes, 0.01-33.1). Data of all determinations for each isolate were pooled, and STs belonging to a given SG were regrouped after observing no significant differences in their capacity to form biofilm.
Antibiotics and other products
Amoxicillin, cefuroxime and ceftriaxone were obtained as the corresponding branded product for human parenteral use complying with the prescriptions of the European Pharmacopoeia (>90% purity) and distributed for clinical use in Belgium as, respectively, Clamoxyl ® and Zinacef ® by GlaxoSmithKline s.a./n.v. (Genval, Belgium) and Rocephin ® by Roche s.a./n.v. (Brussels, Belgium). Clindamycin hydrochloride (potency 92.1%) was obtained from Sigma-Aldrich (St Louis, MO). Clarithromycin and azithromycin (potencies 100%) were from Teva Pharmaceutical Industries (Petah Tikva, Israel); telithromycin (potency 100%) and levofloxacin hemihydrate (potency 97.5%) were from Sanofi-Aventis Deutschland GmbH (Frankfurt, Germany); solithromycin (potency 100%) was from Cempra Pharmaceuticals (Chapel Hill, NC); and moxifloxacin chlorhydrate (potency 90.9%) was from Bayer AG (Leverkusen, Germany). Reserpine was obtained from Fluka (Buchs, Switzerland). All other products were obtained from Sigma-Aldrich or E. Merck AG (Darmstadt, Germany).
Statistical analyses
Unpaired t-test, one-way analysis of variance (ANOVA) and contingency tables were made with GraphPad Prism ® 4.02 and GraphPad InStat ® 3.10 (GraphPad Software Inc., San Diego, CA) and recursive partitioning analyses with JMP ® 10.0.2 (SAS Institute Inc., Cary, NC). Table 1 shows the demographic characteristics of the whole patient population. Most patients were 55-75 years of age. For samples prospectively collected, two hospitals provided a number of samples markedly above the average (in proportion to their bed capacity) owing to their location in or proximity to industrial areas. Most of these patients were living at home prior to hospitalisation and were smokers (more than three-quarters currently active or former deep smokers). Most patients remained hospitalised after reporting. The severity of their disease was equally distributed between low (1 or 2) and high (3 or 4) GOLD scores. Co-morbidity percentages ranged from 20% to 30% for diabetes, cancer and alcoholism, and to 60% for arterial hypertension.
Results
Main characteristics of patients
Correlations between demographic, clinical and pharmaceutical parameters
Associations between demographic factors, severity of disease, co-morbidities and drug usage were examined in 50 patients for whom full medical records were available. Table 2 shows that the length of hospitalisation was clearly correlated with the severity of disease and with tobacco dependence. Older patients had a more severe obstructive syndrome and were more often hypertensive, were poorly vaccinated and showed less incidence of alcoholism.
Serotype/serogroup analyses
Serotyping was performed on all isolates (n = 101). Fig. 1A shows the distribution of STs/SGs amongst the two successive series of isolates (2006-2008 and 2010-2013) stratified by level of coverage (partial or total) with PCV7 [7-valent pneumococcal conjugate vaccine (Prevenar ® ; Wyeth)] and PPV-23 [23-valent pneumococcal polysaccharide vaccine (Pneumo23 ® ; Sanofi-Pasteur MSD)] (the two vaccines in usage at the time during which most isolates were obtained), and for each of these groups by frequency. Whilst there were some changes in ST/SG frequencies between the two series of isolates, SG6 and SG23 were the most prevalent throughout. The second series of isolates also contained a large proportion of SG11 and SG15 strains. There was no marked heterogeneity in ST/SG between the contributing regions (based on patients' living place records; see Supplementary Fig. S1 ). Globally speaking, only 5% of patients hospitalised during the 2010-2013 period had been vaccinated but most isolates were actually from a ST/SG not fully covered by the two vaccines examined (adding the STs covered by the PCV13 did not much change this pattern). Fig. 1B shows the STs/SGs of all isolates when stratified as a function of their ability reported in the literature of being (i) high biofilm producers and causing chronic infections [1, 9] , (ii) low biofilm producers and causing acute infections [9, 14, 21] or (iii) with undescribed ability for these characteristics. Approximately one-half of the isolates were found in the first group. 
Characterisation of the in vitro susceptibility to antibiotics and correlation with the severity of disease and serotypes/serogroups
All of the strains were characterised for their susceptibility to antibiotics focusing on (i) drugs commonly recommended for the ambulatory treatment of bacterial exacerbations of chronic bronchitis in Belgium at the time of the study (amoxicillin, cefuroxime [administered as its axetil prodrug] and moxifloxacin [22] ) and (ii) ceftriaxone (an often prescribed ␤-lactam in hospitals), clarithromycin and azithromycin (often used in combination with a ␤-lactam) and levofloxacin (as an alternative antipneumococcal fluoroquinolone). We also added two ketolides [telithromycin (approved in Europe for the treatment of exacerbations of chronic bronchitis) and solithromycin (still investigational)] because of their reported good activity against S. pneumoniae resistant to macrolides [23] , and tested clindamycin and ciprofloxacin for efflux diagnostic purposes. Cumulative MIC distributions are shown in Fig. 2 (see also Supplementary Fig. S2 ). MIC 50 and MIC 90 values (MIC required to inhibit 50% and 90% of the isolates, respectively) and analysis of the MIC profiles according both to EUCAST and CLSI interpretive criteria are presented in Table 3 for all strains and for each collection individually. There were no significant differences in susceptibilities between the two strain collections. Moreover, largely similar distributions were observed for all three ␤-lactams except in the zones corresponding to their clinical breakpoints, with 6-8% of all isolates falling into the intermediate category for the three drugs and 8-13% in the fully resistant category for amoxicillin and cefuroxime (using, for the latter, the interpretive criteria set for its oral form), but only 1% for ceftriaxone, based on EUCAST interpretive criteria (using CLSI interpretive criteria essentially resulted in having no or only one isolate in the intermediate category). For macrolides, isolates within the first half of the cumulative distribution were globally more susceptible to clarithromycin than azithromycin. The difference, however, largely disappeared for isolates with higher MICs. Resistance rates to clarithromycin and azithromycin reached 28% and 39% based on EUCAST interpretive criteria, and 27% and 29% based on CLSI interpretive criteria. Isolates categorised as intermediate were rare (<10%). The cumulative clindamycin MIC distribution was essentially similar to that of azithromycin, indicating that most of the strains categorised as resistant to this macrolide were of the MLS B type. For fluoroquinolones, moxifloxacin was systematically more active than levofloxacin, but due to the lower breakpoint set by EUCAST for moxifloxacin, more strains (8%) were categorised as being resistant compared with levofloxacin (3%). No meaningful difference with respect to susceptibility was seen if using CLSI breakpoints. For ciprofloxacin, the majority of isolates had a MIC in the intermediate category of EUCAST (no breakpoint set for CLSI). We examined the occurrence of efflux for ciprofloxacin by addition of reserpine. As illustrated in Fig. 3 , there was a shift of the whole population towards lower MICs, with 38% and 35% of the isolates showing a 1 or ≥2 log 2 dilution changes, respectively. Lastly, the cumulative MIC distributions of telithromycin and solithromycin were very similar, with few (EUCAST) or no isolate (CLSI) categorised as resistant (breakpoints for solithromycin have not yet been set). We then examined the correlation between the severity of disease and resistance of the isolates to amoxicillin and cefuroxime by stratifying patients by low (1 or 2) and high (3 or 4) GOLD scores, respectively, and performing a recursive partitioning analysis versus the MICs of their isolates. Whilst this allowed determination of a best MIC split value at 4 mg/L for amoxicillin and at 1 mg/L for cefuroxime, this was not statistically significant (LogWorth values = 0.18 and 0.17, respectively, corresponding to P-values of 0.66 and 0.68). This was further confirmed by 2 × 2 contingency table analysis (P-values of 0.18 and 0.31). Fig. 4 shows the susceptibilities of the strains grouped by ST/SG for each of the antibiotics tested in Fig. 2 and ranked by their mean MIC value (from highest to lowest) with the corresponding EUCAST and CLSI intermediate susceptibility zones. Although the ranking of STs/SGs varied between antibiotics, global trends emerged with ST14, ST19A, SG9, SG29 and SG15 having the highest mean MICs for ␤-lactams, ST19A, SG9, ST14, SG19 and SG 33 for macrolides, ST14, ST19A, SG19, SG9 and SG17 for both ketolides, and ST19A, SG33, ST4, ST5 and SG15 for moxifloxacin and levofloxacin, respectively. All ST19A isolates had a MIC above the EUCAST resistance breakpoint for amoxicillin, cefuroxime, clarithromycin, azithromycin, moxifloxacin and levofloxacin. Conversely, SG7 and ST8 isolates were fully susceptible to all antibiotics (see Supplementary Table S1 for a ranking of all isolates stratified by ST/SG, MICs and resistance pattern).
Biofilm production in relation to pneumococcal susceptibility to antibiotics (minimum inhibitory concentrations and occurrence of efflux)
No significant correlation (one-way ANOVA with Tukey's posttest) was seen between biofilm production (crystal violet staining) and antimicrobial susceptibility (MIC) for each of the antibiotics tested (see data in Supplementary Fig. S3 ). Likewise, there was [20] ) and the Clinical and Laboratory Standards Institute (CLSI) (from >S to <R [19] ), respectively (see Table 3 for values; for clarithromycin, the intermediate zone is the same for EUCAST and CLSI; no clinical breakpoint has been set so far for solithromycin). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 5.
Biofilm production after 10 days of culture for all clinical isolates as a function of their serotype (ST)/serogroup (SG) and ranked from the most to the least productive [using arithmetic means; the box and whiskers show the lowest, the 25 and 75 percentiles, the median and the highest value] (the number of isolates tested for each ST/SG is shown on the abscissa) and of the reference strain Streptococcus pneumoniae ATCC 49619 (ST19F). Each strain was tested twice with three to six measures each time. Strains with STs belonging to a single SG have been pooled (and marked as SG) after having observed no significant differences between these STs. The horizontal dotted line corresponds to the mean value for the reference strain. Strains marked ST correspond to isolates where there was only one serotype. STs/SGs reported in the literature [1, 9] as causing acute infections are marked with an asterisk. CV, crystal violet. no statistically significant correlation (unpaired t-test, Welch corrected) between biofilm production and expression of efflux for macrolides or ciprofloxacin (see data in Supplementary Fig. S4 ). Fig. 5 shows the amount of biomass observed at Day 10 for the reference strain S. pneumoniae ATCC 49619 (ST19F) and for the clinical isolates ranked by inverse amount of production and regrouped by ST/SG. Globally, all isolates, except SG7, SG29 and ST5, produced biofilm in a similar fashion to the reference strains ATCC 49619, with SG22, ST20, SG9, SG27, SG18 and ST8 being the most productive (SG9 and SG22 have been previously reported to be associated with chronic infections [1, 9] ). Conversely, SG7, SG29 and ST5 were the lowest producers in this collection, and these have been reported as poor producers with ST5 and SG7 claimed to be associated with acute infections [9] .
Characterisation of biofilm formation in relation to pneumococcal serotype/serogroup
Discussion
To the best of our knowledge, the present study is one of the first examining in a systematic fashion and correlating the STs/SGs, the resistance pattern and in vitro biofilm formation ability of S. pneumoniae isolates collected from COPD patients with a confirmed diagnosis of AECB. The number of patients and corresponding microbiological samples were limited due to the design of the study, which implied access to the medical history of the patients on the one hand, and the low rate of successful isolation of S. pneumoniae in this patient population on the other hand.
Within these limits, we first confirm and strengthen the close link existing between the severity of COPD and cardiovascular and diabetes pathologies already described in the literature [2, 24] . A decreased ability to breathe reduces mobility, thereby favouring a sedentary lifestyle and weight gain. We next confirm that ␤lactams, levofloxacin and moxifloxacin maintain useful activity against S. pneumoniae isolates from this population, although to a lesser extent than what we saw in a previous study for isolates obtained in Belgium from patients suffering from CAP during the 2006-2009 period [14] . Whilst the two patient populations cannot be directly compared, they nevertheless originate from the same small geographical area, suggesting that we deal, at least partially, with distinct bacterial populations. The lower susceptibility of isolates obtained from COPD patients probably reflects the large and prolonged use of antibiotics in this population before eventually reporting to the hospital (most patients suffering from CAP and included in our previous study had not received any antibiotic when enrolled [14] ). Our findings, therefore, call for caution against the non-documented use of ␤-lactams [especially cefuroxime (given orally as cefuroxime axetil)] in COPD patients. For macrolides, the situation is even more critical as resistance patterns are appalling. Telithromycin, approved in Europe for the treatment of infections caused by ␤-lactamand macrolide-resistant strains, maintains a very high level of activity, probably because of its very low use in Belgium owing to its non-inclusion as a recommended antibiotic for the treatment of AECB in local guidelines [22] (solithromycin is still an investigational drug). Of note is the larger prevalence of efflux for ciprofloxacin, especially if considering the proportion of isolates where a MIC change of ≥2 log 2 dilutions could be observed upon addition of reserpine. Whilst moxifloxacin and levofloxacin were not significantly affected, we know from previous studies that efflux of ciprofloxacin can herald similar changes in MICs for other fluoroquinolones proposed for the treatment of respiratory tract infections such as gemifloxacin and garenoxacin [25] .
Analysis of the susceptibility pattern in relation to their ST/SG shows that some of them (ST19A, ST14, SG9 and SG9) have a high level of resistance to ␤-lactams and macrolides [and decreased susceptibility to ketolides (ST19A and ST14 only)] but not to moxifloxacin (except for ST19A). This is largely akin to our previous findings for isolates from patients suffering from CAP [14] as well as data from other countries in Europe [26] and the Far East [27, 28] . Thus, determination of the prevalent STs/SGs in patients may help in fine-tuning therapy by avoiding the use of antibiotics known to be poorly effective. Determination of the nucleotide sequence of the ␣-helical region of the pneumococcal surface protein (PspA), also proposed as a predictor of multiresistance [28] , could not be examined in the context of the present study.
Turning our attention now to biofilm production, we see that most isolates obtained in this study were high producers (similar to the reference strain ATCC 49619 [ST19F] also known as a high producer [1, 18] ). In the present study, careful attention was paid to obtain data as reproducible as possible for biofilm production. Thus, by and large, this production appears to be a property shared by most isolates from COPD patients, suggesting that previous reports linking poor biofilm production by some of the strains studied here to more acute infections may need revisiting [9] . Conversely, we confirm that strains previously reported to be largely associated with acute infections, such as ST8 and ST3 [1] , are indeed poor biofilm producers.
Lastly, we show no correlation between biofilm formation and intrinsic susceptibility or expression of macrolide or ciprofloxacin efflux in the isolates studied. This could explain why the determination of susceptibility by the reference methods (which use planktonic cells) may fail to truly predict the clinical outcome. Eradication of bacteria from biofilms, indeed, requires antibiotic concentrations to be maintained at values much larger than the breakpoint, especially if considering ␤-lactams and macrolides against mature biofilms [18] . The lack of correlation between biofilm production and ciprofloxacin efflux, which is in contrast with what is observed in Gram-negative bacteria, probably relates to differences in quorum-sensing signalling pathways and the secretion of the corresponding mediators [13, 29, 30] .
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Isolate ranking for each serotype (ST)/serogroup (SG) as a function of their minimum inhibitory concentration (MIC 
